Sometimes, it is necessary to re-learn a previously learned movement behavior, for example, a bad posture during the golf drive or while playing the piano. Unlearning or relearning an intensively trained behavior is particularly important if the behavior is hampering recovery, for example, in chronic pain or after a stroke. With this study, we experimentally test the brain mechanisms that control the change of pre-existing stable memories of a motor skill with electroencephalography (EEG). We will then use non-invasive brain stimulation to modulate these brain mechanisms and test if it is possible to change the pre-existing motor memory and the learning of a new motor skill.

The study includes both a retrospective cross-sectional and prospective longitudinal cohort study design. Demographic and clinical data will be obtained through medical record review. 3-4 blood draws will be collected over the course of the study. If participants were also in the MAC2v3 or NTM PRO Cohort study, data collected for that study will be used in this study. About 450 subjects are expected to participate in this study at 7 research sites in the United States. Participation in this study is expected to last up to 12 months. During that time, participants will have about 3-4 study visits.

This cross-sectional study aims to examine the impact of visual cues on listeners' perception of speaker age. Eligible speaking participants include adult males and females between the ages of 18–90 years old without voice or hearing disorders. Eligibility will be determined by research coordinators via patient demographic forms and validated voice and hearing assessments. Speaking participants will have two audio recordings taken: (1) sustained vowel sound and (2) reading of the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V), a standardized tool employed to evaluate the perceptual characteristics of voice quality across a wide age range. To develop the materials for the listening participants, CAPE-V audio recordings obtained from the speaking participants will be systematically paired with race and age-matched photographs obtained from a publicly available database. The finalized materials will encompass three experimental conditions: (1) audio only, (2) audio presented with a standardized photograph of an individual matched to the speaker's gender and age, and (3) audio presented with a standardized photograph of an individual matched for gender but differing in age. Naïve listening participants, blinded to the experimental conditions, will then be presented with these materials in a randomized order and asked to estimate the perceived ages of the speakers. Additionally, basic acoustic analyses of each sustained vowel sound recording (e.g., jitter, shimmer) will be conducted by a trained professional using the speech analysis software PRAAT.

The purpose of this research study is to assess if the study drug SION-719 is safe and well-tolerated in people with cystic fibrosis who are already taking Trikafta, understand the effect of SION-719 on the body by measuring chloride levels, and to learn how the body absorbs, distributes, and gets rid of the study drug in people with cystic fibrosis. This study is a placebo controlled cross-over study with two study treatment periods, and participants will take part in both study treatment periods. Participants will be assigned either study drug or placebo. Participants will remain on standard dose of physician-prescribed Trikafta throughout the study. This study will be approximately 16 weeks, or 112 days long.

To improve the diagnosis of metabolic dysfunction-steatotic liver disease (MASLD) in primary care, this study will develop, test, and internally validate a predictive model for MASLD in a cross-sectional sample of patients with no known chronic liver disease. Patient metabolic variables, like weight, blood pressure, and blood sugar will be considered for inclusion in the model, and ultrasound-based vibration-controlled elastography will be used for determining the outcome. This work will dramatically enhance MASLD diagnosis and management in primary care.